<DOC>
	<DOCNO>NCT02443077</DOCNO>
	<brief_summary>This randomized phase III trial study ibrutinib see well work compare placebo give stem cell transplant treat patient diffuse large B-cell lymphoma return period improvement ( relapse ) respond treatment ( refractory ) . Before transplant , stem cell take patient stored . Patients receive high dos chemotherapy kill cancer cell make room healthy cell . After treatment , stem cell return patient replace blood-forming cell destroy chemotherapy . Ibrutinib drug may stop growth cancer cell block protein need cell growth . It yet know whether add ibrutinib chemotherapy stem cell transplant may help transplant work well patient relapsed refractory diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Ibrutinib Before After Stem Cell Transplant Treating Patients With Relapsed Refractory Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate ability ibrutinib improve 24-month progression free survival ( PFS ) compare placebo . SECONDARY OBJECTIVES : I . To evaluate ability ibrutinib improve overall survival ( OS ) compare placebo . II . To evaluate ability ibrutinib improve progression free survival ( PFS ) compare placebo . III . To evaluate ability ibrutinib improve post-transplant response rate compare placebo . IV . To evaluate time hematopoietic recovery two arm . V. To evaluate safety tolerability ibrutinib compare placebo . VI . To evaluate incidence secondary malignancy two arm . VII . To evaluate immune reconstitution two arm . TERTIARY OBJECTIVES : I . To assess whether pre-autologous hematopoietic stem cell transplantation ( AutoHCT ) positive fludeoxyglucose F-18 ( FDG ) -positron emission tomography ( PET ) associate inferior 24-month PFS well PFS OS . II . To assess whether pre-AutoHCT FDG-PET result differentially associate 24-month PFS , PFS OS ibrutinib versus placebo arm . III . To evaluate application Lugano criterion change quantitative measurement pre-AutoHCT post AutoHCT ( e.g . delta standard uptake variable [ SUV ] , % SUV decline % metabolic tumor volume [ MTV ] decline , available applicable quantitative measurement ) assess association change variable outcomes , PFS OS . IV . To assess whether glutathione S-transferase theta 1 ( GSTT1 ) null polymorphism correlate pulmonary toxicity BCNU ( carmustine ) -containing condition regimen part autologous stem cell transplantation . V. To assess whether polymorphisms BCNU metabolism pathway BCNU damage repair pathway ( ) associate pulmonary toxicity BCNU-containing conditioning regimen part autologous stem cell transplantation . VI . To evaluate whether propose deoxyribonucleic acid ( DNA ) polymorphism associate toxicity . VII . To assess whether activate mutation breakpoint cluster region ( BCR ) pathway associate response ibrutinib clinical outcome patient treat protocol . VIII . To assess whether phenotypic association immunohistochemistry ( IHC ) marker ( particularly v-myc avian myelocytomatosis viral oncogene homolog [ MYC ] protein expression level ) presence mutation . IX . To assess whether B-cell chronic lymphocytic leukemia ( CLL ) /lymphoma 2 ( BCL2 ) , MYC , antigen Ki67 ( Ki67 ) expression IHC affect clinical outcome patient treat protocol . X . To assess whether translocation MYC without BCL2 BC6 poor outcome patient treat protocol whether ibrutinib modifies prognosis . OUTLINE : Patients randomize 1 2 treatment arm . CONDITIONING REGIMEN : ARM I : Investigators may choose use either BEAMi ( camustine , etoposide , cytarabine , melphalan , ibrutinib ) CBVi ( cyclophosphamide , carmustine , etoposide , ibrutinib ) regimen . BEAMi : Patients receive ibrutinib orally ( PO ) day -6 -1 , carmustine intravenously ( IV ) 2 hour day -6 , etoposide IV twice daily ( BID ) 1-2 hour cytarabine IV BID 1-2 hour day -5 -2 , melphalan IV 20-30 minute day -1 . CBVi : Patients receive carmustine IV 2 hour day -6 , etoposide IV 4 hour day -5 -3 cyclophosphamide IV day -2 . ARM II : Patients receive placebo PO day -6 -1 receive 1 2 conditioning regimen Arm I . TRANSPLANT : In arm , patient undergo autologous hematopoietic progenitor cell bone marrow transplant day 0 . CONTINUATION REGIMEN : ARM I : Beginning 30-36 day transplant , patient receive ibrutinib PO day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . ARM II : Beginning 30-36 day transplant , patient receive placebo PO day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients experience disease progression may crossover Arm I . After completion treatment , patient follow periodically 60 month registration .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<criteria>PREREGISTRATION ELIGIBILITY CRITERIA ( STEP 0 ) Patients must paraffin tissue diagnostic relapse biopsy available submit central pathology review integral molecular subtyping ; review mandatory prior registration confirm eligibility initiate soon possible ; determination celloforigin subtype perform use lymphoma subtyping test ( LST ) assay ELIGIBILITY CRITERIA ( STEP 1 ) Diagnosis World Health Organization ( WHO ) diffuse large Bcell lymphoma , high grade Bcell lymphoma otherwise specify , Bcell lymphoma , unclassifiable , feature intermediate diffuse large Bcell lymphoma Burkitt lymphoma Determination activate Bcelllike ( ABC ) subtype preregistration central review Patient must deem eligible proceed highdose chemotherapy autologous stem cell transplantation local transplant center New York Heart Association class I less ; ordinary physical activity cause undue fatigue , palpitation , dyspnea , angina pain ; patient 60 year old must leave ventricular ejection fraction ( LVEF ) rest &gt; = 40 % measure echocardiogram multigated acquisition ( MUGA ) Diffusion capacity lung carbon monoxide ( DLCO ) &gt; = 40 % predict ( correct hemoglobin ) Forced expiratory volume 1 second ( FEV1 ) &gt; = 40 % predict ( correct hemoglobin ) Forced vital capacity ( FVC ) &gt; = 40 % predict ( correct hemoglobin ) Total Bilirubin = &lt; 1.5 x upper limit normal ( ULN ) unless isolate hyperbilirubinemia attribute Gilbert 's syndrome Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 3 x upper limit normal ( ULN ) Creatinine = &lt; 2.0 mg/dL OR creatinine clearance ( calculated clearance permit ) &gt; = 40 mL/min CockcroftGault formula Prothrombin time ( PT ) / international normalized ration ( INR ) &lt; 1.5 x ULN partial thromboplastin time ( PTT ) ( activate [ ] PTT ) &lt; 1.5 x ULN Patient must progress refractory prior anthracyclinecontaining chemotherapy ( e.g . RCHOP , DAEPOCHR , etc ) No 3 prior regimen large cell component ( e.g . one induction two salvage therapy ) ; monoclonal antibody alone involve field/involved site radiotherapy count line therapy Prior use ibrutinib allow unless patient disease progression receive ibrutinib Patient must chemosensitive disease define least partial response salvage therapy late assessment No major surgery = &lt; 7 day prior registration minor surgery = &lt; 3 day prior registration ( exception intravenous access placement , e.g . Hickman peripherally inserted central catheter [ PICC ] ) Not pregnant nursing ; woman childbearing potential , negative serum pregnancy test must obtain within 14 day prior registration Women childbearing potential must use adequate contraception study start one month last dose protocol therapy ; adequate contraception define hormonal birth control , intrauterine device , double barrier method total abstinence ; men must practice complete abstinence agree use adequate contraception method study start one month last dose protocol therapy Patients require chronic use strong CYP3A inhibitor strong CYP3A inducer Patients require concurrent therapeutic dos steroid ( &gt; 20 mg prednisone/day equivalent ) unless need indication ; steroid discontinue 14 day start protocol treatment Human immunodeficiency virus ( HIV ) infect patient eligible provided meet eligibility criterion , : There prior history acquire immunodeficiency syndrome ( AIDS ) define condition historically low CD4+ Tcell count Bcell lymphoma In opinion expert HIV disease , prospect longterm survival excellent diagnosis lymphoma Use HIV protease inhibitor part antiHIV regimen OR pharmacologic booster allow Zidovudine allow Once daily combination pill HIV contain pharmacologic booster cobicistat allow Patients multidrug resistant HIV eligible Patients : Active central nervous system meningeal involvement lymphoma ; patient history central nervous system ( CNS ) meningeal involvement must document remission cerebrospinal fluid ( CSF ) evaluation contrastenhanced magnetic resonance imaging ( MRI ) image least 91 day prior registration Evidence myelodysplasia cytogenetic abnormality indicative myelodysplasia bone marrow biopsy prior initiation therapy A know bleeding diathesis Requirement warfarin similar vitamin K antagonists ; drug prohibit 28 day prior first treatment throughout trial History stroke intracranial hemorrhage = &lt; 6 month treatment Currently active , clinically significant hepatic impairment ( ChildPugh class B C accord Child Pugh classification History allergic reaction attribute compound similar chemical biologic composition ibrutinib agent use study Serologic status reflect active hepatitis B C infection ; patient positive hepatitis B core antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody must negative polymerase chain reaction ( PCR ) prior enrollment ; ( PCR positive patient exclude ) Eastern Cooperative Oncology Group ( ECOG ) performance status must = &lt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>